300529 健帆生物
已收盘 08-16 15:00:00
资讯
新帖
简况
【机构调研记录】长盛基金调研新洋丰、健帆生物等4只个股(附名单)
证券之星 · 08-12
【机构调研记录】长盛基金调研新洋丰、健帆生物等4只个股(附名单)
【机构调研记录】富荣基金调研炬芯科技、健帆生物
证券之星 · 08-12
【机构调研记录】富荣基金调研炬芯科技、健帆生物
【机构调研记录】安信基金调研健帆生物、百济神州等3只个股(附名单)
证券之星 · 08-12
【机构调研记录】安信基金调研健帆生物、百济神州等3只个股(附名单)
健帆生物:8月8日召开分析师会议,华泰证券、嘉实基金等多家机构参与
证券之星 · 08-09
健帆生物:8月8日召开分析师会议,华泰证券、嘉实基金等多家机构参与
健帆生物(300529)8月8日主力资金净买入791.78万元
证券之星 · 08-09
健帆生物(300529)8月8日主力资金净买入791.78万元
健帆生物(300529)2024年中报简析:营收净利润同比双双增长
证券之星 · 08-09
健帆生物(300529)2024年中报简析:营收净利润同比双双增长
国金证券:给予健帆生物买入评级
证券之星 · 08-08
国金证券:给予健帆生物买入评级
图解健帆生物中报:第二季度单季净利润同比增230.63%
证券之星 · 08-08
图解健帆生物中报:第二季度单季净利润同比增230.63%
健帆生物最新公告:上半年净利润5.53亿元 同比增长99.1%
证券之星 · 08-07
健帆生物最新公告:上半年净利润5.53亿元 同比增长99.1%
健帆生物获得实用新型专利授权:“一种滴壶组件及血液透析设备”
证券之星 · 08-07
健帆生物获得实用新型专利授权:“一种滴壶组件及血液透析设备”
7月31日健帆生物涨7.91%,天弘中证500指数增强A基金重仓该股
证券之星 · 07-31
7月31日健帆生物涨7.91%,天弘中证500指数增强A基金重仓该股
健帆生物(300529)7月25日主力资金净卖出567.57万元
证券之星 · 07-26
健帆生物(300529)7月25日主力资金净卖出567.57万元
健帆生物(300529)7月23日主力资金净买入123.64万元
证券之星 · 07-24
健帆生物(300529)7月23日主力资金净买入123.64万元
截至7月15日,按照申万一级行业,已有92家生物医药企业披露2024年上半年业绩预告。按预告归母净利润下限统计,近六成公司实现增长,其中22家公司净利同比倍增,创新和国际化成为企业业绩增长的重要推动力。
华尔街见闻 · 07-17
截至7月15日,按照申万一级行业,已有92家生物医药企业披露2024年上半年业绩预告。按预告归母净利润下限统计,近六成公司实现增长,其中22家公司净利同比倍增,创新和国际化成为企业业绩增长的重要推动力。
国投证券7月16日发布研报称,给予健帆生物(300529.SZ)买入评级。评级理由主要包括:1)公司发布2024年半年度业绩预告;
智通财经 · 07-16
国投证券7月16日发布研报称,给予健帆生物(300529.SZ)买入评级。评级理由主要包括:1)公司发布2024年半年度业绩预告;
健帆生物新提交1件商标注册申请
证券之星 · 07-12
健帆生物新提交1件商标注册申请
健帆生物(300529)7月9日主力资金净买入2601.80万元
证券之星 · 07-10
健帆生物(300529)7月9日主力资金净买入2601.80万元
国金证券7月10日发布研报称,给予健帆生物(300529.SZ)买入评级。评级理由主要包括:1)新产品迭代叠加应用领域拓展贡献长期额外增长极;
智通财经 · 07-10
国金证券7月10日发布研报称,给予健帆生物(300529.SZ)买入评级。评级理由主要包括:1)新产品迭代叠加应用领域拓展贡献长期额外增长极;
健帆生物最新公告:上半年净利同比预增90%—110%
证券之星 · 07-08
健帆生物最新公告:上半年净利同比预增90%—110%
健帆生物:上半年净利同比预增90%-110%健帆生物发布业绩预告,预计上半年净利润5.27亿元—5.83亿元,同比增长90%—110%。
格隆汇 · 07-08
健帆生物:上半年净利同比预增90%-110%健帆生物发布业绩预告,预计上半年净利润5.27亿元—5.83亿元,同比增长90%—110%。
加载更多
公司概况
公司名称:
健帆生物科技集团股份有限公司
所属行业:
专用设备制造业
上市日期:
2016-08-02
主营业务:
健帆生物科技集团股份有限公司主要从事生物材料和高科技医疗器械的研发、生产及销售。主要产品有血液灌流器、血液净化设备、血液透析粉液产品。公司先后获评为国家火炬计划重点高新技术企业、国家制造业单项冠军示范企业、国家技术创新示范企业、国家知识产权示范企业。荣获国家科技进步二等奖、广东省科学技术进步一等奖。
发行价格:
10.80
{"stockData":{"symbol":"300529","market":"SZ","secType":"STK","nameCN":"健帆生物","latestPrice":25.85,"timestamp":1723791780000,"preClose":26,"halted":0,"volume":3100179,"delay":0,"floatShares":521000000,"shares":807000000,"eps":0.8812,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.15,"latestTime":"08-16 15:00:00","open":26.07,"high":26.09,"low":25.73,"amount":80170100,"amplitude":0.0138,"askPrice":25.91,"askSize":20,"bidPrice":25.85,"bidSize":7,"shortable":0,"etf":0,"ttmEps":0.8812,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1724031000000},"adr":0,"adjPreClose":26,"symbolType":"stock","openAndCloseTimeList":[[1723771800000,1723779000000],[1723784400000,1723791600000]],"highLimit":28.6,"lowLimit":23.4,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":807451312,"pbRate":7.19,"roa":"--","roe":"16.91%","epsLYR":0.55,"committee":0.28866,"marketValue":20873000000,"floatMarketCap":13476000000,"peRate":29.334997,"changeRate":-0.0058,"turnoverRate":0.0059,"status":1},"requestUrl":"/m/hq/s/300529","defaultTab":"news","newsList":[{"id":"2458612793","title":"【机构调研记录】长盛基金调研新洋丰、健帆生物等4只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2458612793","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458612793?lang=zh_cn&edition=full","pubTime":"2024-08-12 08:01","pubTimestamp":1723420917,"startTime":"0","endTime":"0","summary":"4)分众传媒 个股亮点:公司生产并销售watchman智能手表;公司被阿里150亿战略入股,持股10.3%,未来或继续增持不超过5%;公司已与方源资本成立体育基金,共同领投咕咚3000万美元长盛基金成立于1999年,截至目前,资产管理规模925.3亿元,排名62/204;资产管理规模671.79亿元,排名62/204;管理公募基金数133只,排名50/204;旗下公募基金经理19人,排名67/204。旗下最近一年表现最佳的公募基金产品为长盛中证申万一带一路分级B,最新单位净值为1.8,近一年增长40.96%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081200001626.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0027","300529","BK0229","BK0188","000902","BK0251"],"gpt_icon":0},{"id":"2458361275","title":"【机构调研记录】富荣基金调研炬芯科技、健帆生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2458361275","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458361275?lang=zh_cn&edition=full","pubTime":"2024-08-12 08:01","pubTimestamp":1723420891,"startTime":"0","endTime":"0","summary":"旗下最近一年表现最佳的公募基金产品为富荣富祥纯债A,最新单位净值为1.18,近一年增长5.58%。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081200001569.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0214","BK0251","688049","300529"],"gpt_icon":0},{"id":"2458612718","title":"【机构调研记录】安信基金调研健帆生物、百济神州等3只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2458612718","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458612718?lang=zh_cn&edition=full","pubTime":"2024-08-12 08:01","pubTimestamp":1723420888,"startTime":"0","endTime":"0","summary":"3)分众传媒 个股亮点:公司生产并销售watchman智能手表;公司被阿里150亿战略入股,持股10.3%,未来或继续增持不超过5%;公司已与方源资本成立体育基金,共同领投咕咚3000万美元安信基金成立于2011年,截至目前,资产管理规模1167.9亿元,排名55/204;资产管理规模1007.02亿元,排名48/204;管理公募基金数172只,排名34/204;旗下公募基金经理33人,排名37/204。旗下最近一年表现最佳的公募基金产品为安信丰泽39个月定开债,最新单位净值为1.01,近一年增长10.73%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081200001563.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0251","688235","LU0588546209.SGD","BK1588","BK1161","LU0307460666.USD","300529","BK1500","LU1969619763.USD","06160","BK1583","LU2328871848.SGD"],"gpt_icon":0},{"id":"2458133563","title":"健帆生物:8月8日召开分析师会议,华泰证券、嘉实基金等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2458133563","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458133563?lang=zh_cn&edition=full","pubTime":"2024-08-09 18:41","pubTimestamp":1723200101,"startTime":"0","endTime":"0","summary":"证券之星消息,2024年8月9日健帆生物发布公告称公司于2024年8月8日召开分析师会议,华泰证券、嘉实基金、华夏基金、长信基金、富荣基金、博时基金、交银施罗德基金、安信基金、国投瑞银基金、建信基金、中庚基金、中信建投证券、长盛基金、国信证券、西南证券、国金证券、国投证券、中金公司、申万宏源证券、太平洋证券参与。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024080900041136.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","LU1781817850.SGD","LU1934453819.USD","BK0028","BK0276","BK0183","300529","LU1064131003.USD","LU1328615791.USD","LU1979443071.USD","LU1064130708.USD","BK0012","BK0251","BK0188","601688","LU1580142542.USD"],"gpt_icon":0},{"id":"2458330130","title":"健帆生物(300529)8月8日主力资金净买入791.78万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2458330130","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458330130?lang=zh_cn&edition=full","pubTime":"2024-08-09 09:21","pubTimestamp":1723166465,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年8月8日收盘,健帆生物报收于26.24元,下跌3.35%,换手率2.03%,成交量10.57万手,成交额2.76亿元。近5日资金流向一览见下表:健帆生物融资融券信息显示,融资方面,当日融资买入1228.48万元,融资偿还1273.32万元,融资净偿还44.84万元。健帆生物主营业务:生物材料和高科技医疗器械的研发、生产及销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024080900014621.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300529","BK0251"],"gpt_icon":0},{"id":"2458794983","title":"健帆生物(300529)2024年中报简析:营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2458794983","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458794983?lang=zh_cn&edition=full","pubTime":"2024-08-09 06:06","pubTimestamp":1723154795,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期健帆生物发布2024年中报。根据财报显示,健帆生物营收净利润同比双双增长。截至本报告期末,公司营业总收入14.96亿元,同比上升47.77%,归母净利润5.53亿元,同比上升99.1%。营业利润变动幅度为99.39%,原因:本期销售收入增加,单位生产成本、期间费用率同比下降。支付的各项税费变动幅度为88.21%,原因:收入、利润同比增加,缴纳税款同比增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024080900010723.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300529"],"gpt_icon":0},{"id":"2457331447","title":"国金证券:给予健帆生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2457331447","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457331447?lang=zh_cn&edition=full","pubTime":"2024-08-08 12:21","pubTimestamp":1723090906,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司袁维,何冠洲近期对健帆生物进行研究并发布了研究报告《各领域产品高速增长,盈利质量持续提高》,本报告对健帆生物给出买入评级,当前股价为26.21元。肝科产品销售收入同比增长112%,重症领域相关耗材产品销售收入同比增长72%。最新盈利预测明细如下:该股最近90天内共有3家机构给出评级,买入评级3家;过去90天内机构目标均价为40.09。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024080800022721.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300529"],"gpt_icon":0},{"id":"2457827419","title":"图解健帆生物中报:第二季度单季净利润同比增230.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2457827419","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457827419?lang=zh_cn&edition=full","pubTime":"2024-08-08 01:23","pubTimestamp":1723051385,"startTime":"0","endTime":"0","summary":"证券之星消息,健帆生物2024年中报显示,公司主营收入14.96亿元,同比上升47.77%;归母净利润5.53亿元,同比上升99.1%;扣非净利润5.26亿元,同比上升99.99%;其中2024年第二季度,公司单季度主营收入7.51亿元,同比上升70.91%;单季度归母净利润2.68亿元,同比上升230.63%;单季度扣非净利润2.55亿元,同比上升248.33%;负债率44.21%,投资收益817.93万元,财务费用809.71万元,毛利率80.54%。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024080800001752.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300529"],"gpt_icon":0},{"id":"2457947890","title":"健帆生物最新公告:上半年净利润5.53亿元 同比增长99.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2457947890","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457947890?lang=zh_cn&edition=full","pubTime":"2024-08-07 17:40","pubTimestamp":1723023613,"startTime":"0","endTime":"0","summary":"健帆生物披露半年报,公司上半年实现营业收入14.96亿元,同比增长47.77%;净利润5.53亿元,同比增长99.1%;基本每股收益0.69元。报告期内,公司整体毛利率为80.54%,其中血液灌流器产品毛利率为84.46%,具备强劲的盈利能力和市场竞争力。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024080700037125.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300529"],"gpt_icon":0},{"id":"2457703320","title":"健帆生物获得实用新型专利授权:“一种滴壶组件及血液透析设备”","url":"https://stock-news.laohu8.com/highlight/detail?id=2457703320","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457703320?lang=zh_cn&edition=full","pubTime":"2024-08-07 02:31","pubTimestamp":1722969117,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示健帆生物新获得一项实用新型专利授权,专利名为“一种滴壶组件及血液透析设备”,专利申请号为CN202322214439.1,授权日为2024年8月6日。本实用新型通过在压力监测管上设置第一促凝管,能够阻止血液继续流至第一传感器保护器,避免血液流入血液透析设备,造成漏血和血液污染的问题。今年以来健帆生物新获得专利授权14个,较去年同期减少了12.5%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024080700003665.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300529","BK0251"],"gpt_icon":0},{"id":"2455906432","title":"7月31日健帆生物涨7.91%,天弘中证500指数增强A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2455906432","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455906432?lang=zh_cn&edition=full","pubTime":"2024-07-31 16:48","pubTimestamp":1722415681,"startTime":"0","endTime":"0","summary":"证券之星消息,7月31日健帆生物涨7.91%,收盘报26.75元,换手率1.75%,成交量9.11万手,成交额2.36亿元。根据2024基金半年报公募基金重仓股数据,重仓该股的公募基金共13家,其中持有数量最多的公募基金为天弘中证500指数增强A。天弘中证500指数增强A目前规模为21.06亿元,最新净值0.9753,较上一交易日下跌0.4%,近一年下跌17.28%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024073100034257.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","000001.SH","159982","399905","300529","000905.SH"],"gpt_icon":0},{"id":"2454491353","title":"健帆生物(300529)7月25日主力资金净卖出567.57万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2454491353","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2454491353?lang=zh_cn&edition=full","pubTime":"2024-07-26 09:22","pubTimestamp":1721956953,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年7月25日收盘,健帆生物报收于26.19元,下跌1.98%,换手率0.95%,成交量4.93万手,成交额1.31亿元。近5日资金流向一览见下表:健帆生物融资融券信息显示,融资方面,当日融资买入724.49万元,融资偿还733.88万元,融资净偿还9.4万元。健帆生物主营业务:血液灌流相关产品的研发、生产与销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072600013932.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300529"],"gpt_icon":0},{"id":"2453019812","title":"健帆生物(300529)7月23日主力资金净买入123.64万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2453019812","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453019812?lang=zh_cn&edition=full","pubTime":"2024-07-24 09:19","pubTimestamp":1721783970,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年7月23日收盘,健帆生物报收于27.2元,下跌4.83%,换手率1.4%,成交量7.28万手,成交额2.02亿元。近5日资金流向一览见下表:健帆生物融资融券信息显示,融资方面,当日融资买入1563.55万元,融资偿还715.23万元,融资净买入848.32万元。健帆生物主营业务:血液灌流相关产品的研发、生产与销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072400016904.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300529","BK0251"],"gpt_icon":0},{"id":"2452594290","title":"截至7月15日,按照申万一级行业,已有92家生物医药企业披露2024年上半年业绩预告。按预告归母净利润下限统计,近六成公司实现增长,其中22家公司净利同比倍增,创新和国际化成为企业业绩增长的重要推动力。","url":"https://stock-news.laohu8.com/highlight/detail?id=2452594290","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452594290?lang=zh_cn&edition=full","pubTime":"2024-07-17 04:01","pubTimestamp":1721160094,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"live_wallstreetcn","url":"https://wallstreetcn.com/live/a-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/live/a-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_wallstreetcn","symbols":["BK1191","BK0185","BK0012","159982","BK0187","BK0070","BK0201","399441","600521","BK0197","300529","000001.SH","BK0183","SG9999014674.SGD","LU0405327494.USD","BK0251","301301","BK0239","BK0188","600420","399300","002001","BK0082","BK0191","BK0132","BK0020","161726","LU0405327148.USD","09989","BK0175","BK0196","BK0028","002399","000423","BK0010"],"gpt_icon":0},{"id":"2451108601","title":"国投证券7月16日发布研报称,给予健帆生物(300529.SZ)买入评级。评级理由主要包括:1)公司发布2024年半年度业绩预告;","url":"https://stock-news.laohu8.com/highlight/detail?id=2451108601","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2451108601?lang=zh_cn&edition=full","pubTime":"2024-07-16 06:35","pubTimestamp":1721082910,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=astock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK0251","161027","300529"],"gpt_icon":0},{"id":"2450327870","title":"健帆生物新提交1件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2450327870","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2450327870?lang=zh_cn&edition=full","pubTime":"2024-07-12 13:04","pubTimestamp":1720760689,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示,近日健帆生物科技集团股份有限公司新提交1件商标注册申请。商标申请详情如下:今年以来健帆生物科技集团股份有限公司新申请注册商标3件,截止目前公司共持有注册商标184件,另有4件商标尚在注册申请中。数据来源:企查查以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071200023243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300529"],"gpt_icon":0},{"id":"2450886154","title":"健帆生物(300529)7月9日主力资金净买入2601.80万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2450886154","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2450886154?lang=zh_cn&edition=full","pubTime":"2024-07-10 09:21","pubTimestamp":1720574509,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年7月9日收盘,健帆生物报收于26.59元,下跌1.26%,换手率2.31%,成交量12.06万手,成交额3.23亿元。近5日资金流向一览见下表:健帆生物融资融券信息显示,融资方面,当日融资买入4372.27万元,融资偿还2680.22万元,融资净买入1692.04万元。健帆生物主营业务:血液灌流相关产品的研发、生产与销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071000015462.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300529"],"gpt_icon":0},{"id":"2450072320","title":"国金证券7月10日发布研报称,给予健帆生物(300529.SZ)买入评级。评级理由主要包括:1)新产品迭代叠加应用领域拓展贡献长期额外增长极;","url":"https://stock-news.laohu8.com/highlight/detail?id=2450072320","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2450072320?lang=zh_cn&edition=full","pubTime":"2024-07-10 07:56","pubTimestamp":1720569386,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=astock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["300529","BK0251"],"gpt_icon":0},{"id":"2449704207","title":"健帆生物最新公告:上半年净利同比预增90%—110%","url":"https://stock-news.laohu8.com/highlight/detail?id=2449704207","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2449704207?lang=zh_cn&edition=full","pubTime":"2024-07-08 20:59","pubTimestamp":1720443584,"startTime":"0","endTime":"0","summary":"健帆生物发布业绩预告,预计上半年净利润5.27亿元—5.83亿元,同比增长90%—110%。报告期内,公司外部政策环境得到一定改善。公司持续发挥在血液灌流领域的科技及市场领先优势,在肾病、肝病、危急重症等领域业务发展态势良好,实现公司营业收入同比增长。公司以增效降本原则开展各类经营活动,产量规模增加有效降低了单位生产成本,同时期间费用率同比下降。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070800031315.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300529","BK0251"],"gpt_icon":0},{"id":"2449777071","title":"健帆生物:上半年净利同比预增90%-110%健帆生物发布业绩预告,预计上半年净利润5.27亿元—5.83亿元,同比增长90%—110%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2449777071","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2449777071?lang=zh_cn&edition=full","pubTime":"2024-07-08 20:56","pubTimestamp":1720443373,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["300529","BK0251"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2016-08-02","address":"广东省珠海市香洲区高新区科技六路98号","stockEarnings":[{"period":"1week","weight":0.0019},{"period":"1month","weight":-0.1105},{"period":"3month","weight":-0.0935},{"period":"6month","weight":0.2812},{"period":"1year","weight":0.1573},{"period":"ytd","weight":0.1797}],"companyName":"健帆生物科技集团股份有限公司","boardCode":"AI0035","perCapita":"10622股","boardName":"专用设备制造业","registeredCapital":"80745万元","compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":-0.0282},{"period":"3month","weight":-0.0871},{"period":"6month","weight":0.0047},{"period":"1year","weight":-0.0899},{"period":"ytd","weight":-0.0321}],"survey":" 健帆生物科技集团股份有限公司主要从事生物材料和高科技医疗器械的研发、生产及销售。主要产品有血液灌流器、血液净化设备、血液透析粉液产品。公司先后获评为国家火炬计划重点高新技术企业、国家制造业单项冠军示范企业、国家技术创新示范企业、国家知识产权示范企业。荣获国家科技进步二等奖、广东省科学技术进步一等奖。","serverTime":1723828048707,"listedPrice":10.8,"stockholders":"49076人(较上一季度减少9.25%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"健帆生物(300529)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供健帆生物(300529)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"健帆生物,300529,健帆生物股票,健帆生物股票老虎,健帆生物股票老虎国际,健帆生物行情,健帆生物股票行情,健帆生物股价,健帆生物股市,健帆生物股票价格,健帆生物股票交易,健帆生物股票购买,健帆生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"健帆生物(300529)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供健帆生物(300529)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}